China Sinopharm chief rules out high price for coronavirus vaccine | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
May 29, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, MAY 29, 2025
China Sinopharm chief rules out high price for coronavirus vaccine

Coronavirus chronicle

Reuters
18 August, 2020, 06:25 pm
Last modified: 18 August, 2020, 06:26 pm

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • Children aged 5-11 to get Covid jabs from 11 August

China Sinopharm chief rules out high price for coronavirus vaccine

Sinopharm has said its experimental vaccine could be ready for public use by the end of this year. It has entered a late-stage human test in the United Arab Emirates to gather proof of efficacy for final regulatory approvals

Reuters
18 August, 2020, 06:25 pm
Last modified: 18 August, 2020, 06:26 pm
FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo
FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo

A potential coronavirus vaccine being developed by a unit of China National Pharmaceutical Group (Sinopharm) could cost no more than 1,000 yuan ($144.27) for two shots, state media on Tuesday quoted chairman Liu Jingzhen as saying.

Sinopharm has said its experimental vaccine could be ready for public use by the end of this year. It has entered a late-stage human test in the United Arab Emirates to gather proof of efficacy for final regulatory approvals.

"It will not be priced very high. It is expected to cost a few hundred yuan for a shot, and for two shots it should be less than 1,000 yuan," Liu told the Guangming Daily newspaper.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Governments and drugmakers around the world are in a frenetic race to develop a Covid-19 vaccine. More than 200 candidates are in development, including more than 20 in human clinical trials.

Moderna Inc said earlier this month that smaller volumes of its experimental vaccine have been priced at $32-$37 per dose.

Last month, the US government struck a deal for an experimental vaccine being developed by Pfizer and partner BioNTech SE that secures enough to innoculate 50 million Americans for about $40 a person.

Sinopharm's Liu did not mention whether China's state-backed nationwide insurance program would cover some of the vaccine costs for consumers, or whether it could be included in the country's free vaccination scheme.

China National Biotec Group (CNBG), a Sinopharm unit, has moved two vaccine strains using the same method into human trials. Its plants in Wuhan and Beijing combined could make over 200 million doses of the drug annually.

($1 = 6.9316 Chinese yuan renminbi)

Sinopharm / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • How termination of USDA-funded trade facilitation project will affect Bangladesh
    How termination of USDA-funded trade facilitation project will affect Bangladesh
  • File photo of Bangladesh Secretariat. Photo: Collected
    Visitors banned from entering Secretariat on Mondays and Thursdays
  • File photo of BNP Secretary General Mirza Fakhrul Islam Alamgir. Photo: Collected
    Asked for roadmap, govt didn’t give in 10 months, now 'December it is': Mirza Fakhrul

MOST VIEWED

  • Google Pay. Photo: Collected
    Google Pay likely coming to Bangladesh soon
  • Graphics: TBS
    Suspicious banking activities surge by 56% since July: Cenbank
  • Representational image of cable car/Freepik
    Cable car to be installed from Himchari to Reju Khal in Marine Drive Road
  • Illustration: TBS
    Bangladesh sees highest-ever per capita income of $2,820 in FY25, BBS provisional data shows
  • IFIC Bank receives Tk6,000 cr in new deposits in six months
    IFIC Bank receives Tk6,000 cr in new deposits in six months
  • Abdul Awal Mintoo, chairman of National Bank Limited. Sketch: TBS
    'Regulatory support must for National Bank to restore depositors' confidence'

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • Children aged 5-11 to get Covid jabs from 11 August

Features

In recent years, the Gor-e-Shaheed Eidgah has emerged as a strong contender for the crown of the biggest Eid congregation in the country, having hosted 600,000 worshippers in 2017. Photo: TBS

Gor-e-Shaheed Boro Maath: The heart of Dinajpur

2d | Panorama
The Hili Land Port, officially opened in 1997 but with trade roots stretching back to before Partition, has grown into a cornerstone of bilateral commerce.

Dhaka-Delhi tensions ripple across Hili’s markets and livelihoods

3d | Panorama
Photo: Collected

Desk goals: Affordable ways to elevate your study setup

3d | Brands
Built on a diamond-type frame, the Hornet 2.0 is agile but grounded. PHOTO: Asif Chowdhury

Honda Hornet 2.0: Same spirit, upgraded sting

3d | Wheels

More Videos from TBS

The fight between two brothers; Adidas vs Puma

The fight between two brothers; Adidas vs Puma

4h | Others
Trump is again keen to make Canada the 51st state

Trump is again keen to make Canada the 51st state

6h | Others
Trump's tariff strategy and Europe's investment politics, violence or negotiation?

Trump's tariff strategy and Europe's investment politics, violence or negotiation?

7h | Others
Rumours surrounding the Club World Cup: Which club will Ronaldo join?

Rumours surrounding the Club World Cup: Which club will Ronaldo join?

7h | Others
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net